If you pin testosterone and your HDL drops from 45 to 35, that is expected pharmacology. If you add Trenbolone and your HDL drops to 9, that is a different category of risk. Understanding the lipid impact spectrum across compounds is not academic curiosity — it is the difference between a cycle that manages risk and one that accumulates it silently.
The data is clear: AAS universally suppress HDL and often elevate LDL and ApoB. But the magnitude varies enormously. Some compounds produce barely measurable changes at typical doses. Others produce lipid profiles that would alarm any cardiologist. Here is the full compound-by-compound breakdown, ranked by lipid impact from mildest to most severe.
Before we dive into individual compounds, here is the full landscape. The table below ranks every major AAS by its impact on HDL, LDL, and ApoB, based on published literature and anonymized data from our user database.
AAS Lipid Impact Spectrum (ranked mildest to worst)
| Marker | Compound | HDL Suppression |
|---|---|---|
| Testosterone (TRT: 100-200 mg/wk) | -5 to -15% | Minimal LDL change |
| Primobolan (< 400 mg/wk) | -10 to -20% | Minimal LDL change |
| Testosterone (Blast: 300-600 mg/wk) | -20 to -40% | Mild LDL elevation |
| Nandrolone (300-600 mg/wk) | -20 to -35% | Moderate ApoB elevation |
| Boldenone / EQ (400-800 mg/wk) | -30 to -50% | Significant ApoB elevation |
| Oxandrolone / Anavar (20-50 mg/day) | -25 to -50% | Moderate LDL elevation |
| Turinabol (20-50 mg/day) | -30 to -50% | Moderate LDL elevation |
| Trenbolone (200-500 mg/wk) | -60 to -90% | Severe ApoB elevation |
| Oxymetholone / Anadrol (50-150 mg/day) | -70 to -90% | Severe HDL drop + liver stress |
| Stanozolol / Winstrol (25-50 mg/day) | -70 to -90% | Most lipid-toxic per mg |
| Superdrol (10-30 mg/day) | -80 to -95% | Extreme across all markers |
| Fluoxymesterone / Halotestin (10-40 mg/day) | -80 to -95% | Rapid, severe suppression |
These ranges represent typical responses. Individual variation exists — some users tolerate certain compounds better than others. But the ranking order is consistent across studies and our user data. The compounds at the bottom of this table produce lipid values that are not just "elevated" or "suppressed" but qualitatively different from what is seen with moderate-dose testosterone alone.
If lipid preservation is your priority, these compounds are your best options. Their impact on HDL, LDL, and ApoB is modest at typical doses, and recovery is rapid after cessation.
Testosterone: The Baseline
Primobolan (Methenolone) is frequently cited as the mildest compound on lipids, and the data supports this — at doses below 400 mg per week. Users report HDL drops of 10-20 percent, and LDL changes are minimal. The catch is that Primobolan is also relatively mild in anabolic effect, so users often stack it with other compounds, which complicates the lipid picture. As a standalone compound, however, it is the closest thing to a "lipid-neutral" AAS.
Nandrolone (Deca-Durabolin) occupies a middle position that is worth understanding. Its impact on HDL is moderate — typically 20-35 percent suppression at 300-600 mg per week. But nandrolone has a unique lipid signature: it tends to raise ApoB more than its HDL suppression would suggest. A 2018 study in Steroids measured ApoB changes in nandrolone users and found that ApoB elevation was disproportionate to the HDL drop. This means that if you use nandrolone, you absolutely need to measure ApoB, not just HDL and LDL. Many users assume "moderate HDL suppression = moderate overall impact," but with nandrolone, the ApoB story tells a different picture.
ApoB (Apolipoprotein B)
These compounds produce meaningful lipid changes that require monitoring but are generally manageable with appropriate lifestyle interventions and compound selection.
Boldenone (Equipoise, EQ) presents a specific challenge: it causes significant HDL suppression (30-50 percent) while also elevating hematocrit more than most other injectables. The combination of suppressed HDL and elevated hematocrit creates a cardiovascular risk profile that requires active management. EQ users should monitor both markers simultaneously and be prepared to intervene if HDL drops below 20 mg/dL or hematocrit exceeds 54 percent.
💡Among moderate-impact compounds, Boldenone stands out for its dual effect on lipids and hematocrit. Users who stack EQ with other compounds see HDL values that are 15-25 percent lower than users running testosterone alone at equivalent doses.
— GearCheck User Data
Oxandrolone (Anavar) is often perceived as "mild" because it is well-tolerated in other respects. Lipids tell a different story. At 20-50 mg per day, Anavar reduces HDL by 25-50 percent — comparable to much more androgenic compounds. The reason Anavar gets a "moderate" rather than "severe" rating is that its impact on LDL and ApoB is less dramatic than the worst offenders, and recovery is relatively fast (4-6 weeks). However, a 50 percent HDL reduction is not mild by any reasonable standard. Users who run Anavar for extended periods (8+ weeks) should expect HDL in the 20-30 mg/dL range.
Turinabol produces a lipid profile similar to Anavar: moderate-to-significant HDL suppression with manageable LDL changes. The clinical literature on Turinabol is thinner than on Anavar, but user data suggests comparable lipid impact at equivalent doses. One advantage of Turinabol is its shorter half-life, which allows for more flexible dosing that may reduce cumulative lipid exposure.
These compounds produce lipid values that enter pathological territory. HDL below 15 mg/dL is common. HDL below 10 mg/dL is documented. At these levels, the distinction between "expected pharmacology" and "genuine risk" blurs — because few interventions can restore HDL from single digits while the compound remains on board.
The Lipid-Toxic Tier
Trenbolone is the most studied of the severe-impact compounds, and the data is consistent: HDL drops of 60-90 percent are typical. Users on 200-500 mg of Trenbolone per week frequently report HDL values between 8 and 15 mg/dL — levels that would normally warrant pharmacological intervention in a non-AAS context. ApoB elevation is equally severe. A 2019 case series in the Journal of Clinical Lipidology documented ApoB values exceeding 180 mg/dL in Trenbolone users, a level associated with a five-fold increase in cardiovascular risk in the general population.
Oxymetholone (Anadrol) combines severe HDL suppression (70-90 percent) with significant liver enzyme elevation due to its 17-alpha-alkylated structure. Anadrol's lipid impact is compounded by its tendency to elevate blood pressure and hematocrit, creating a triple threat: lipid suppression, volume expansion, and hepatic stress. Users who add Anadrol to a cycle see HDL values that are typically 30-50 percent lower than on the base testosterone dose alone, within the first two weeks of use.
Stanozolol (Winstrol) may be the most lipid-toxic compound per milligram. At just 25-50 mg per day, it produces HDL suppression comparable to 500 mg of Trenbolone. The oral route and 17-alpha-alkylated structure mean first-pass hepatic effects compound the lipid impact. Winstrol is unique in that even short cycles (4 weeks) produce significant and measurable HDL reduction.
Superdrol (Methasterone) and Halotestin (Fluoxymesterone) represent the extreme end of the spectrum. Both produce HDL suppression above 80 percent at typical doses. Halotestin is particularly notable for the speed of its effect — HDL drops measurably within days of first administration. Clinical data on these compounds is limited due to their absence from approved medical use, but user-reported values consistently place them at the top of the lipid-toxicity ranking.
Why Severe HDL Suppression Matters
Our anonymized database tracks real-world lipid values across hundreds of AAS users. These numbers complement published research by showing what happens in uncontrolled, real-world conditions — where dosing varies, compounds are stacked, and lifestyle factors differ. Here is what the data shows for the most commonly used compounds:
Average HDL Values by Compound (GearCheck User Database)
| Marker | Compound | Median HDL on Compound |
|---|---|---|
| Testosterone only (200-400 mg/wk) | 32 mg/dL | 15-20 pts below baseline |
| Testosterone + Primobolan (<400 mg) | 35 mg/dL | Mildest combination in our data |
| Testosterone + Nandrolone | 28 mg/dL | Moderate + ApoB risk |
| Testosterone + Boldenone | 24 mg/dL | Significant + HCT interaction |
| Testosterone + Anavar | 25 mg/dL | Worse than expected for "mild" oral |
| Testosterone + Trenbolone | 14 mg/dL | Severe, often < 10 mg/dL |
| Testosterone + Anadrol | 12 mg/dL | Severe + liver + BP |
| Testosterone + Winstrol | 11 mg/dL | Most lipid-toxic per mg |
Two patterns stand out in our data. First, the base dose of testosterone matters less than the additional compound. A user on 200 mg testosterone plus 300 mg Trenbolone will have worse lipids than a user on 600 mg testosterone alone. The "add-on" compound is the dominant driver of lipid impact. Second, individual variability is substantial. In every compound category, the standard deviation is roughly 25-30 percent of the mean. Some users tolerate even severe compounds reasonably well, while others experience dramatic changes at moderate doses.
The ApoB/ApoA1 Ratio: Why It Matters More Than LDL
If you only measure one advanced lipid marker, make it the ApoB/ApoA1 ratio. This ratio captures the balance between atherogenic particles (ApoB, carried by every VLDL, IDL, LDL, and Lp(a) particle) and anti-atherogenic particles (ApoA1, the primary structural protein of HDL). A growing body of evidence suggests this ratio outperforms LDL cholesterol, non-HDL cholesterol, and even ApoB alone as a predictor of cardiovascular risk.
The INTERHEART study, a landmark case-control study published in The Lancet involving nearly 30,000 participants across 52 countries, found that the ApoB/ApoA1 ratio was the single strongest lipid-related predictor of heart attack risk — stronger than LDL, stronger than total cholesterol, and stronger than the total/HDL ratio that many clinicians still rely on. Among AAS users, this ratio matters even more because AAS distort both sides of the equation simultaneously: AAS drive ApoB up while driving ApoA1 down, creating a double hit that a standard lipid panel captures poorly.
Here is how to interpret the ratio and what it means in the context of AAS use:
ApoB/ApoA1 Ratio Interpretation
| Marker | Risk Category | Ratio Range |
|---|---|---|
| Optimal (non-AAS) | < 0.6 | Low cardiovascular risk; excellent particle balance |
| Optimal (on AAS) | < 0.8 | Achievable with mild compounds at moderate doses |
| Borderline elevated | 0.8 – 1.2 | Common with moderate compounds or higher doses |
| High risk | 1.2 – 2.0 | Typical with Trenbolone, Anadrol, Winstrol |
| Severe risk | > 2.0 | Seen with stacked severe compounds; warrants intervention |
The clinical relevance is straightforward. A user on 300 mg of Trenbolone per week might have total cholesterol of 180 mg/dL — a value that looks fine on a standard lipid panel — but an ApoB of 160 mg/dL and an ApoA1 of 80 mg/dL, yielding a ratio of 2.0. That same user's physician, looking only at the standard panel, would see nothing alarming. The ApoB/ApoA1 ratio reveals risk that would otherwise go undetected.
ApoA1
Why the Ratio Matters More on AAS
When the compound is removed, how long do lipids take to return to baseline? The answer depends on the severity of suppression, the compound involved, and individual factors. Here is what the evidence and our data suggest:
Recovery Is Proportional to Severity
One nuance worth noting: ApoB elevation often persists longer than HDL suppression. A user might see HDL return to 35 mg/dL within 6 weeks of stopping Trenbolone, but ApoB may remain elevated at 120+ mg/dL for 12 weeks or more. This means that "lipid recovery" based on a standard panel (which does not include ApoB) can be misleading. If you measure only HDL and LDL, you might conclude your lipids have normalized when your atherogenic particle count is still elevated.
The recovery timeline also depends on whether you have built up cumulative damage from multiple cycles. First-time users of a severe compound typically see full recovery within 12-16 weeks. But someone who has run Trenbolone three times in two years may find that their HDL stabilizes at 28-32 mg/dL rather than returning to their pre-AAS baseline of 45-50 mg/dL. A 2019 study in the Journal of Clinical Endocrinology and Metabolism followed 35 long-term AAS users (average 5+ years) and found that HDL remained significantly suppressed even after 12 months of abstinence in 40% of subjects. This suggests a threshold effect: beyond a certain cumulative exposure, lipid changes may become semi-permanent.
ApoB Recovery Lag
Practical recovery protocol: Test lipids (full panel including ApoB and ApoA1) at 4 weeks post-cycle, then again at 12 weeks post-cycle. If HDL has returned to within 10% of baseline by week 12, recovery is on track. If ApoB remains above 110 mg/dL at week 12 despite HDL normalization, extend monitoring to week 16 and consider adding ApoB-lowering supplements (omega-3s at 3-4 g/day, bergamot polyphenols). If neither HDL nor ApoB has substantially recovered by week 12, investigate further — you may have a pre-existing lipid condition that AAS unmasked, or cumulative damage from prior cycles.
How do you choose compounds based on your starting lipid profile? The decision tree depends on where you are before the cycle begins.
Starting HDL Above 40 mg/dL: Good Starting Point
Starting HDL Between 25-40 mg/dL: Moderate Caution
Starting HDL Below 25 mg/dL: High Caution
Beyond compound choice, there are practical steps that make a measurable difference. Cardiovascular exercise (30+ minutes daily) consistently produces 5-10 percent HDL improvements in users across all compound categories. Omega-3 supplementation at 3-4 grams of EPA+DHA per day reduces ApoB by 10-15 percent in most users. And perhaps most importantly, avoiding the combination of severe compounds — stacking Trenbolone with Winstrol, for example — is not just additive but synergistic in lipid damage. The worst lipid profiles in our database consistently come from stacks of multiple severe compounds, not from any single one.
The Real Risk Is Cumulative
Evidence-Based Lipid Support During Cycle
No supplement can fully neutralize the lipid impact of severe AAS. But several have demonstrated measurable benefits in clinical trials and user data. Here is a tiered protocol based on the strength of evidence and expected effect size.
Tier 1: High evidence, moderate effect (5-15% improvement)
Omega-3 fatty acids (EPA + DHA) — This is the most well-supported intervention for AAS users. At 3-4 grams of combined EPA and DHA per day (not 3-4 grams of fish oil, but 3-4 grams of the active fatty acids), omega-3s reduce ApoB by 10-15%, lower triglycerides by 15-30%, and provide anti-inflammatory effects that partially offset the vascular impact of dyslipidemia. A 2020 meta-analysis in the Journal of the American Heart Association covering 40+ trials found that EPA-predominant formulations (at least 2 g/day EPA) produced the most consistent cardiovascular benefit. For AAS users specifically, omega-3s appear to blunt the ApoB rise even when HDL suppression continues — making them particularly valuable for preserving the ApoB/ApoA1 ratio. Choose a high-concentration ethyl ester or triglyceride-form product and split the dose AM/PM to improve absorption.
Fiber (soluble, 10-25 g/day) — Psyllium husk, beta-glucan (oat fiber), and glucomannan bind bile acids in the gut, forcing the liver to use cholesterol for bile production instead of releasing it into circulation. The effect on LDL is 5-10% reduction — modest but additive with other interventions. Most AAS users consume far less fiber than optimal due to high-meat diets. Adding 10 grams of psyllium before two meals per day is a practical starting point.
Tier 2: Moderate evidence, small to moderate effect (5-10% improvement)
Bergamot polyphenolic extract — Bergamot contains unique flavonoids (brutieridin and melitidin) that act as statin-like HMG-CoA reductase inhibitors with additional antioxidant effects. Clinical studies show LDL reductions of 15-25% and HDL increases of 5-10% at 500-1000 mg/day of standardized extract. Bergamot is particularly interesting for AAS users because it appears to work through multiple pathways — inhibiting cholesterol synthesis while also improving HDL function. One small Italian study in 2019 found that bergamot extract partially reversed HDL dysfunction in metabolic syndrome patients, suggesting it might help with the HDL quality problem that AAS create.
CoQ10 (ubiquinol, 200-300 mg/day) — Statins deplete CoQ10 because the same pathway (HMG-CoA reductase) produces both cholesterol and CoQ10. AAS may create a similar metabolic bottleneck. CoQ10 is not a lipid-lowering agent, but it supports mitochondrial function in the heart and vascular endothelium — particularly relevant when lipids are under stress. Ubiquinol (the reduced form) has better bioavailability and is preferred for athletes.
Tier 3: Limited evidence, use with caution
Red yeast rice — Contains monacolin K, which is chemically identical to lovastatin. It lowers LDL by 15-25% in most users. However, red yeast rice products vary wildly in potency (some contain virtually no active ingredient, while others contain statin levels equivalent to prescription doses). Quality control is inconsistent, and the active compound carries the same muscle and liver risks as prescription statins. If you use red yeast rice, choose a brand with third-party verification and monitor liver enzymes and creatine kinase. A better approach: discuss low-dose rosuvastatin (2.5-5 mg/day) with a physician who understands AAS use — it is more predictable, better studied, and safer with proper monitoring.
Niacin (nicotinic acid) — Niacin raises HDL more effectively than any other supplement (15-35% in clinical trials). However, its use in AAS users is complicated. Niacin also causes prostaglandin-mediated flushing (manageable with the no-flush inositol hexaniacinate form, though the lipid benefits may differ), raises blood glucose, and can elevate liver enzymes at high doses (2+ g/day). For AAS users already dealing with liver stress from oral compounds, niacin's hepatic effects are a genuine concern. If you use niacin, limit to 500-1000 mg/day of immediate-release nicotinic acid, take with food, and monitor ALT/AST and fasting glucose.
Start Before Cycle
Begin omega-3s (3-4 g EPA+DHA/day), soluble fiber, and bergamot extract 2-4 weeks before your cycle starts. This establishes a lipid baseline on the supplements before AAS begin altering your metabolism. Measure full lipid panel including ApoB and ApoA1 at this point.
Recheck at Mid-Cycle (Week 4-6)
If HDL has dropped more than 40% from baseline or ApoB has risen above 120 mg/dL, escalate interventions. Add CoQ10 200 mg/day if not already taking it. Consider whether your compound selection is appropriate for your lipid tolerance.
Post-Cycle Recovery Support
Continue all supplements for at least 8 weeks after cycle end. The weeks immediately following compound cessation are when reverse cholesterol transport is most active — your body is clearing the lipid debris. Maintain omega-3s and fiber during this period. Retest at week 12 post-cycle to confirm recovery.
Supplements Are Support, Not Salvation
Cholesterol on AAS is not a simple story of "steroids are bad for your lipids." It is a spectrum that ranges from barely measurable to profoundly pathological. Testosterone at moderate doses produces manageable changes. Primobolan at reasonable doses is the mildest option available. Anavar and Turinabol are surprisingly impactful for their reputation. And Trenbolone, Anadrol, Winstrol, Superdrol, and Halotestin form a tier of compounds that produce lipid values that enter genuinely concerning territory.
The practical implication is straightforward: if you care about cardiovascular longevity, choose your compounds with the same precision you apply to dosing, training, and diet. The evidence is clear that compound choice is the single most powerful lever for lipid management on cycle. No supplement, no lifestyle intervention, and no medication can fully compensate for choosing a severe-impact compound when a moderate one would achieve your goals.